Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen sold 1,500 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $14.87, for a total transaction of $22,305.00. Following the transaction, the senior vice president now directly owns 34,838 shares in the company, valued at approximately $518,041. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 0.27% on Monday, hitting $15.03. The stock had a trading volume of 487,294 shares. Albany Molecular Research has a 1-year low of $7.75 and a 1-year high of $15.14. The stock’s 50-day moving average is $11.28 and its 200-day moving average is $11.80. The company has a market cap of $482.2 million and a price-to-earnings ratio of 37.47.

Albany Molecular Research (NASDAQ:AMRI) last announced its earnings results on Wednesday, February 12th. The company reported $0.22 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.17 by $0.05. On average, analysts predict that Albany Molecular Research will post $0.77 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on AMRI shares. Analysts at McLean Capital Management upgraded shares of Albany Molecular Research from a “neutral” rating to a “buy” rating in a research note on Friday. Analysts at Sterne Agee downgraded shares of Albany Molecular Research from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 3rd. They now have a $12.00 price target on the stock, down previously from $15.00.

Albany Molecular Research, Inc (NASDAQ:AMRI) provides scientific services, technologies and products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.